EVGN (Evogene) Cyclically Adjusted PS Ratio: (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVGN Evogene Ltd EVGN
33 GF Score
Price $0.54
GF Value $0.39
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Evogene Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evogene  (NAS:EVGN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Evogene Cyclically Adjusted PS Ratio Related Terms


Evogene Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Evogene's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evogene Cyclically Adjusted PS Ratio Chart

Evogene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.35 4.67 1.55 0.95

Evogene Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 1.09 1.11 0.95 0.00

EVGN vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Evogene's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evogene's Cyclically Adjusted PS Ratio falls into.


EVGN
33GF Score
Evogene Ltd EVGN
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evogene Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Evogene's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Evogene's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Evogene Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.729 241.018 0.999
201609 0.601 241.428 0.822
201612 0.461 241.432 0.631
201703 0.283 243.801 0.383
201706 0.459 244.955 0.619
201709 0.290 246.819 0.388
201712 0.285 246.524 0.382
201803 0.142 249.554 0.188
201806 0.147 251.989 0.193
201809 0.143 252.439 0.187
201812 0.247 251.233 0.325
201903 0.135 254.202 0.175
201906 0.075 256.143 0.097
201909 0.038 256.759 0.049
201912 0.045 256.974 0.058
202003 0.029 258.115 0.037
202006 0.116 257.797 0.149
202009 0.117 260.280 0.148
202012 0.103 260.474 0.131
202103 0.085 264.877 0.106
202106 0.033 271.696 0.040
202109 0.037 274.310 0.045
202112 0.076 278.802 0.090
202203 0.058 287.504 0.067
202206 0.076 296.311 0.085
202209 0.113 296.808 0.126
202212 0.157 296.797 0.175
202303 0.154 301.836 0.168
202306 0.156 305.109 0.169
202309 0.767 307.789 0.823
202312 -0.409 306.746 -0.440
202403 0.824 312.332 0.871
202406 0.119 314.175 0.125
202409 0.300 315.301 0.314
202412 0.227 315.605 0.238
202503 0.360 319.799 0.372
202506 0.108 322.561 0.111
202509 0.036 324.800 0.037
202512 0.036 324.054 0.037
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Evogene (EVGN) Overvalued in 2026?

Based on GuruFocus' analysis, Evogene stock appears to be overvalued. The current stock price of $0.54 is trading 39.1% above its estimated GF Value™ of $0.39. GuruFocus considers Evogene to be Significantly Overvalued.

Key valuation signals for EVGN:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $0.39 vs. price of $0.54 (39.1% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the EVGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evogene Business Description

Other Exchanges EVGN:Israel
Address 13 Gad Feinstein Street, Park Rehovot, Ness Ziona, Rehovot, ISR, 7638517
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
33GF Score

Get the complete analysis for EVGN

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.39
GF Value